Anika Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Anika Therapeutics, Inc. (ANIK) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.63 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense › Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-03
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.63M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.91M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.82M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $3.88M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.79M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $3.63M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $3.91M 10-K · filed 2026-03-03 | |
| 2023-12-31 | $3.82M 10-K · filed 2025-03-17 | $3.88M 10-K · filed 2024-03-15 |
| 2022-12-31 | $2.79M 10-K · filed 2024-03-15 | |
| 2021-12-31 | $2.78M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $1.74M 10-K · filed 2022-03-11 | |
| 2019-12-31 | $1.90M 10-K/A · filed 2021-04-26 | |
| 2018-12-31 | $3.15M 10-K · filed 2020-03-06 | |
| 2017-12-31 | $2.31M 10-K · filed 2019-02-27 | |
| 2016-12-31 | $1.88M 10-K · filed 2018-02-27 | |
| 2015-12-31 | $1.04M 10-K · filed 2017-02-24 | |
| 2014-12-31 | $755.00K 10-K · filed 2016-03-10 | $755.04K 10-K · filed 2015-03-13 |
| 2013-12-31 | $1.36M 10-K · filed 2015-03-13 | |
| 2012-12-31 | $1.58M 10-K · filed 2014-03-13 | |
| 2011-12-31 | $1.50M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |